Trials / Completed
CompletedNCT06903715
A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)
An Open-Label, Phase 1 Study to Characterize the Effects of Phenytoin on the Pharmacokinetics of Belzutifan in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Researchers designed belzutifan, the study medicine, to treat certain kinds of cancer. The goal of this study is to learn what happens to belzutifan in a healthy person's body over time when taken, by mouth, as a tablet. Researchers will learn what happens when belzutifan is taken alone and when it is taken after several days of treatment with phenytoin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Belzutifan | Oral administration |
| DRUG | Phenytoin | Oral administration |
Timeline
- Start date
- 2025-03-28
- Primary completion
- 2025-05-08
- Completion
- 2025-05-27
- First posted
- 2025-04-01
- Last updated
- 2025-06-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06903715. Inclusion in this directory is not an endorsement.